Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

Rhea-AI Summary

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a late-stage biopharmaceutical company, announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023, at 10:45 AM ET. The presentation will be accessible to registered viewers, and investors can request one-on-one meetings through their Sidoti representative or Citius Investor Relations. Citius focuses on developing first-in-class critical care products, with ongoing projects like Mino-Lok® and I/ONTAK, aimed at addressing critical health challenges.

CRANFORD, N.J., Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023.

Conference Details: 

Date:	Wednesday, January 18, 2023
Time:	10:45 AM ET
Location:	Virtual
Live presentation:	Viewers must register for the conference to view the live presentation.
1x1 meetings:	Investors may request meetings by contacting their Sidoti representative or Citius Investor Relations.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in CTCL, for which a BLA is under review by the FDA.  Mino-Lok® was granted Fast Track designation by the FDA. I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-sidoti-micro-cap-virtual-conference-on-january-18-2023-301718781.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When will Citius Pharmaceuticals present at the Sidoti Micro-Cap Virtual Conference?

Citius Pharmaceuticals will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023, at 10:45 AM ET.

What is the focus of Citius Pharmaceuticals?

Citius Pharmaceuticals is focused on developing first-in-class critical care products, particularly in oncology and anti-infectives.

How can investors participate in Citius Pharmaceuticals' conference presentation?

Investors can view the live presentation by registering for the conference.

What are the key products in Citius Pharmaceuticals' pipeline?

Key products include Mino-Lok®, an antibiotic lock solution, and I/ONTAK (E7777), an IL-2R immunotherapy for CTCL.

How can investors request one-on-one meetings with Citius Pharmaceuticals?

Investors can request meetings by contacting their Sidoti representative or reaching out to Citius Investor Relations.